Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype

Nature Medicine

Volumn 16, Issue 1, 2010, Pages 49-58

  Starczynowski, Daniel T ^a,b   Kuchenbauer, Florian ^a   Argiropoulos, Bob ^a   Sung, Sandy ^a   Morin, Ryan ^a   Muranyi, Andrew ^a   Hirst, Martin ^a   Hogge, Donna ^a   Marra, Marco ^a   Wells, Richard A ^c   Buckstein, Rena ^c   Lam, Wan ^a,b   Humphries, R Keith ^a,b   Karsan, Aly ^a,b  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Sunnybrook Health Sciences Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; MICRORNA; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW DEPRESSION; CHROMOSOME 5Q; CHROMOSOME DELETION 5; CLINICAL FEATURE; CONTROLLED STUDY; DYSPLASIA; GENE EXPRESSION; GENE TARGETING; GENETIC CODE; HAPLOIDY; HEMATOPOIETIC STEM CELL; HUMAN; INNATE IMMUNITY; MEDIATOR; MEGAKARYOPOIESIS; MOUSE; NEUTROPENIA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOCYTE COUNT; THROMBOCYTOSIS;

ANIMALS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; GENE KNOCKDOWN TECHNIQUES; HAPLOTYPES; HUMANS; MEGAKARYOCYTES; MEMBRANE GLYCOPROTEINS; MICE; MICRORNAS; MYELODYSPLASTIC SYNDROMES; PHENOTYPE; RECEPTORS, INTERLEUKIN-1; TNF RECEPTOR-ASSOCIATED FACTOR 6;

MUS;

EID: 73849121794     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2054     Document Type: Article

References (47)

1. Corey, S.J. et al. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat. Rev. Cancer 7, 118-129 (2007).
2. Nilsson, L. et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 96, 2012-2021 (2000).
3. Nilsson, L. et al. The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes. Blood 110, 3005-3014 (2007).
4. Thanopoulou, E. et al. Engraftment of NOD/SCID-β2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome. Blood 103, 4285-4293 (2004).
5. Nimer, S.D. Myelodysplastic syndromes. Blood 111, 4841-4851 (2008).
6. Li, X., Bryant, C.E. & Deeg, H.J. Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome. Int. J. Hematol. 80, 140-145 (2004).
7. Giagounidis, A.A., Germing, U. & Aul, C. Biological and prognostic signifcance of chromosome 5q deletions in myeloid malignancies. Clin. Cancer Res. 12, 5-10 (2006).
8. Boultwood, J. et al. Narrowing and genomic annotation of the commonly deleted region of the 5q-syndrome. Blood 99, 4638-4641 (2002).
9. Martíinez-Ramirez, A. et al. Analysis of myelodysplastic syndromes with complex karyotypes by high-resolution comparative genomic hybridization and subtelomeric CGH array. Genes Chromosom. Cancer 42, 287-298 (2005).
10. Wang, L. et al. Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays. Haematologica 93, 994-1000 (2008).
11. Ebert, B.L. et al. Identifcation of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 451, 335-339 (2008).
12. Bartel, D.P. MicroRNAs: genomics, biogenesis, mechanism and function. Cell 116, 281-297 (2004).
13. Ebert, M.S., Neilson, J.R. & Sharp, P.A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 4, 721-726 (2007).
14. Gentner, B. et al. Stable knockdown of microRNA in vivo by lentiviral vectors. Nat. Methods 6, 63-66 (2009).
15. Bigoni, R. et al. Multilineage involvement in the 5q-syndrome: a fuorescent in situ hybridization study on bone marrow smears. Haematologica 86, 375-381 (2001).
16. Kroef, M.J. et al. Mosaicism of the 5q deletion as assessed by interphase FISH is a common phenomenon in MDS and restricted to myeloid cells. Leukemia 11, 519-523 (1997).
17. Lewis, B.P., Shih, I.H., Jones-Rhoades, M.W., Bartel, D.P. & Burge, C.B. Prediction of mammalian microRNA targets. Cell 115, 787-798 (2003).
18. Taganov, K.D., Boldin, M.P., Chang, K.J. & Baltimore, D. NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. USA 103, 12481-12486 (2006).
19. Lamothe, B. et al. Site-specifc Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I κ B kinase activation. J. Biol. Chem. 282, 4102-4112 (2007).
20. Mansell, A., Brint, E., Gould, J.A., O'Neill, L.A. & Hertzog, P.J. Mal interacts with tumor necrosis factor receptor-associated factor (TRAF)-6 to mediate NF-κB activation by Toll-like receptor (TLR)-2 and TLR4. J. Biol. Chem. 279, 37227-37230 (2004).
21. Wang, C. et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412, 346-351 (2001).
22. Nimer, S.D. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. J. Clin. Oncol. 24, 2576-2582 (2006).
23. Kishimoto, T. Interleukin-6: from basic science to medicine\-40 years in immunology. Annu. Rev. Immunol. 23, 1-21 (2005).
24. Garzon, R. et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111, 3183-3189 (2008).
25. Marcucci, G. et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 358, 1919-1928 (2008).
26. Takada, S. et al. MicroRNA expression profles of human leukemias. Leukemia 22, 1274-1278 (2008).
27. Rakoff-Nahoum, S. & Medzhitov, R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317, 124-127 (2007).
28. Bhaumik, D. et al. Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells. Oncogene 27, 5643-5647 (2008).
29. Chen, H. et al. Interference with nuclear factor κ B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis. Oncogene 25, 6520-6527 (2006).
30. Maratheftis, C.I., Andreakos, E., Moutsopoulos, H.M. & Voulgarelis, M. Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes. Clin. Cancer Res. 13, 1154-1160 (2007). (Pubitemid 46424055)
31. Hofmann, W.K. et al. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 100, 3553-3560 (2002).
32. Gondek, L.P. et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD and MDS-derived AML. Blood 111, 1534-1542 (2008).
33. Starczynowski, D.T. et al. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood 112, 3412-3424 (2008).
34. Garzon, R. et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc. Natl. Acad. Sci. USA 105, 3945-3950 (2008).
35. Garzon, R. et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111, 3183-3189 (2008).
36. Jongen-Lavrencic, M., Sun, S.M., Dijkstra, M.K., Valk, P.J. & Lowenberg, B. MicroRNA expression profling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 111, 5078-5085 (2008).
37. Li, Z. et al. Distinct microRNA expression profles in acute myeloid leukemia with common translocations. Proc. Natl. Acad. Sci. USA 105, 15535-15540 (2008).
38. Takada, S. et al. MicroRNA expression profles of human leukemias. Leukemia 22, 1274-1278 (2008).
39. Hast, R., Eriksson, M., Widell, S., Arvidsson, I. & Bemell, P. Neutrophil dysplasia is not a specifc feature of the abnormal chromosomal clone in myelodysplastic syndromes. Leuk. Res. 23, 579-584 (1999).
40. Herold, M., Schmalzl, F. & Zwierzina, H. Increased serum interleukin 6 levels in patients with myelodysplastic syndromes. Leuk. Res. 16, 585-588 (1992).
41. Verhoef, G.E. et al. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 6, 1268-1272 (1992).
42. Hsu, H.C. et al. Circulating levels of thrombopoietic and infammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome. Oncology 63, 64-69 (2002).
43. Brandt, S.J., Bodine, D.M., Dunbar, C.E. & Nienhuis, A.W. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J. Clin. Invest. 86, 592-599 (1990).
44. Hawley, R.G., Fong, A.Z., Burns, B.F. & Hawley, T.S. Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus. J. Exp. Med. 176, 1149-1163 (1992).
45. Corral, L.G. et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J. Immunol. 163, 380-386 (1999).
46. Nagai, Y. et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity 24, 801-812 (2006).
47. Tang, M. et al. TAK1 is required for the survival of hematopoietic cells and hepatocytes in mice. J. Exp. Med. 205, 1611-1619 (2008).